Related Experiment Video
Updated: Mar 1, 2026
12:16
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
15.6K
Summary
Chimeric antigen receptor T-cell therapy targeting BCMA shows promise for multiple myeloma. This treatment was well-tolerated and led to complete, lasting remissions in patients with relapsed or refractory disease.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Multiple myeloma is a hematologic malignancy.
- Relapsed/refractory multiple myeloma presents significant treatment challenges.
Purpose of the Study:
- To evaluate the safety and efficacy of chimeric antigen receptor T cells targeting BCMA in patients with multiple myeloma.
Main Methods:
- Phase I clinical trial in China.
- Chimeric antigen receptor T cells engineered to target B-cell maturation antigen (BCMA).
Main Results:
- Preliminary results indicate the therapy is well-tolerated.
- Complete and durable responses observed in patients with relapsed/refractory multiple myeloma.
Conclusions:
- BCMA-targeted CAR T-cell therapy is a potential therapeutic option for multiple myeloma.
- The therapy demonstrated promising safety and efficacy in early-phase trials.
